Fluicell

Executive Summary

Fluicell is a Swedish biotechnology company pioneering a universal tissue production platform called Nexocyte™, which leverages high-resolution single-cell bioprinting to create advanced tissue models and transplantable tissues. Founded in 2012 and headquartered in Gothenburg, the company initially focuses on developing functional tissues to cure type 1 diabetes, while also offering drug screening services to pharmaceutical partners. Its technology enables precise placement of individual cells, allowing for the recreation of complex tissue architectures with high viability and functionality. The company's lead program aims to generate insulin-producing pancreatic islets for transplantation, addressing a significant unmet need in diabetes care. Fluicell's platform also holds promise for other regenerative medicine applications and could accelerate drug discovery by providing more physiologically relevant in vitro models. With a strong intellectual property portfolio and growing industry interest, Fluicell is positioned for potential partnerships and funding to advance its pipeline. However, as a private early-stage company, it faces typical risks in manufacturing scalability and regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data release for Nexocyte-derived pancreatic islets in type 1 diabetes70% success
• Q1 2027Partnership with a major pharmaceutical company for drug screening services60% success
• Q2 2026Series A funding round completion80% success